Reynolds American beats sales expectations, while profit matches

Reynolds American Inc. reported on Tuesday a third-quarter profit that rose to $781 million, or 46 cents a share, from $505 million, or 44 cents a share, in the same period a year ago. Excluding non-recurring items, such as asset impairment charges, the cigarette seller said adjusted earnings per share came to 55 cents, matching the FactSet consensus. Revenue rose 41% to $3.16 billion, beating the FactSet consensus of $3.08 billion. Domestic cigarette volume increased 30%, boosted by the addition of the Newport brand, while industry cigarette volume declined 2.2%. For the full-year, the company now expects adjusted EPS of $1.94 to $2.00, compared with the FactSet consensus of $1.99. The stock, which was still inactive in premarket trade, has soared 54% year to date, while the S&P 500 has ticked up 0.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Pfizer’s stock jumps after beating profit and sales expectations, raising outlook

Pfizer Inc.’s stock climbed 1.9% in premarket trade Tuesday, after the drug giant reported better-than-expected third-quarter results and raised its full-year outlook. Earnings fell to $2.13 billion, or 34 cents a share, from $2.67 billion, or 42 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to 60 cents, beating the FactSet consensus of 51 cents. Revenue slipped 2% to $12.09 billion, but was above the FactSet consensus of $11.56 billion, boosted by strong growth in its innovative products, vaccines and global oncology businesses. The company raised its full-year 2015 outlook for adjusted EPS to a range of $2.16 to $2.20 from $2.04 to $2.10, and for revenue to $47.5 billion to $48.5 billion from $46.5 billion to $47.5 billion. “We have been intently focused on seeking to generate a greater portion of our earnings from increased revenues and I see our product portfolio, product pipeline and recent business development activity as supporting this objective,” said Chief Executive Ian Read. The stock has gained 9.7% year to date, while the Dow Jones Industrial Average has slipped 1.1%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Cheesecake Factory sinks on weak quarterly revenue

Cheesecake Factory Inc. shares slumped late Monday after the restaurant chain reported disappointing quarterly revenue. Cheesecake Factory said third-quarter earnings rose to $26.2 million, or 52 cents a share, from $24.2 million, or 48 cents a share, a year ago. On an adjusted basis, the casual dining company would have earned 59 cents a share, better than the 56 cents a share forecast by analysts in a FactSet survey. Revenue grew to $526.7 million from $499.1 million but fell short of $535 million projected. Shares of Cheesecake Factory slumped 5.8% in after-hours trading.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

XTera to sell up to 5.5 million shares at $9-$11 a piece

Network infrastructure provider XTera Communications Inc. will offer 5.5 million shares in its initial public offering, expecting the shares to price between $9 and $11 a piece, according to a filing Monday setting the terms of the previously announced IPO. The company will trade on the Nasdaq under the symbol XCOM. BMO Capital Markets, Cowen & Co. Needham & Co. are among the underwriters.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Trivascular Tech shares jump on Endologix acquisition deal

Trivascular Technologies Inc. shares jumped in the extended session Monday after Endologix Inc. agreed to acquire the medical device company for $211 million in stock and cash. Trivascular shares surged 55% to $7.80, but still fell short of the transaction value of $9.10 a share. Endologix shares were flat at $13.73. Trivascular also said it expects third-quarter revenue of $9.5 million, while analysts surveyed by FactSet expect $9.3 million.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News